You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFlurazepam
Accession NumberDB00690  (APRD00983)
TypeSmall Molecule
GroupsApproved, Illicit
DescriptionA benzodiazepine derivative used mainly as a hypnotic. [PubChem]
Structure
Thumb
Synonyms
Flurazepam
Flurazépam
Flurazepamum
Insumin
External Identifiers
  • ID 480
  • Ro 5-6901
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bio-flurazepamcapsule30 mgoralBiomed Pharma2004-04-23Not applicableCanada
Bio-flurazepamcapsule15 mgoralBiomed Pharma2004-04-23Not applicableCanada
Dalmanecapsule15 mgoralValeant Canada Lp/valeant Canada s.e.c.1971-12-312016-07-08Canada
Dalmanecapsule30 mgoralValeant Canada Lp/valeant Canada s.e.c.1971-12-312016-07-08Canada
Flurazepamcapsule30 mgoralAa Pharma Inc1982-12-31Not applicableCanada
Flurazepamcapsule15 mgoralAa Pharma Inc1982-12-31Not applicableCanada
Flurazepam 15capsule15 mgoralPro Doc Limitee1982-12-31Not applicableCanada
Flurazepam 15mg Capsulecapsule15 mgoralLaboratoires Confab IncNot applicableNot applicableCanada
Flurazepam 30capsule30 mgoralPro Doc Limitee1982-12-31Not applicableCanada
Flurazepam 30mg Capsulecapsule30 mgoralLaboratoires Confab IncNot applicableNot applicableCanada
Novo-flupam Cap 15mgcapsule15 mgoralNovopharm Limited1980-12-312000-08-25Canada
Novo-flupam Cap 30mgcapsule30 mgoralNovopharm Limited1980-12-312001-03-30Canada
PMS-flurazepam Cap 15mgcapsule15 mgoralPharmascience Inc1986-12-31Not applicableCanada
PMS-flurazepam Cap 30mgcapsule30 mgoralPharmascience Inc1986-12-311996-09-10Canada
Riva-flurazepam 15mg Capsulescapsule15 mgoralLaboratoire Riva Inc1999-11-262003-07-28Canada
Riva-flurazepam 30mg Capsulescapsule30 mgoralLaboratoire Riva Inc1999-11-262003-07-28Canada
Som-pamcapsule15 mgoralBiomed Pharma1981-12-31Not applicableCanada
Som-pamcapsule30 mgoralBiomed Pharma1981-12-31Not applicableCanada
Somnol 15mgtablet15 mgAxxess Pharma Inc.1981-12-312011-07-22Canada
Somnol 30mgtablet30 mgAxxess Pharma Inc.1981-12-312011-07-22Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Flurazepamcapsule30 mg/1oralWest ward Pharmaceutical Corp1986-12-08Not applicableUs
Flurazepamcapsule15 mg/1oralWest ward Pharmaceutical Corp1986-12-08Not applicableUs
Flurazepamcapsule30 mg/1oralH.J. Harkins Company, Inc.1986-12-08Not applicableUs
Flurazepamcapsule30 mg/1oralGolden State Medical Supply, Inc.1986-12-08Not applicableUs
Flurazepamcapsule30 mg/1oralA S Medication Solutions Llc1986-12-08Not applicableUs
Flurazepamcapsule30 mg/1oralbryant ranch prepack1986-12-08Not applicableUs
Flurazepamcapsule30 mg/1oralPreferred Pharmaceuticals, Inc2012-01-27Not applicableUs
Flurazepamcapsule30 mg/1oralRebel Distributors Corp1986-12-08Not applicableUs
Flurazepam Hydrochloridecapsule30 mg/1oralPd Rx Pharmaceuticals, Inc.2010-07-16Not applicableUs
Flurazepam Hydrochloridecapsule15 mg/1oralMylan Pharmaceuticals Inc.1985-11-27Not applicableUs
Flurazepam Hydrochloridecapsule30 mg/1oralMylan Pharmaceuticals Inc.1985-11-27Not applicableUs
Flurazepam Hydrochloridecapsule15 mg/1oralPhysicians Total Care, Inc.1995-05-08Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DalmadormMeda
Dalmadorm mediumMeda
FelisonSIT
FlunoxTeofarma
SompanI.C.N.
ValdormValeas
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Flurazepam Hydrochloride
36105-20-1
Thumb
  • InChI Key: PUGVROXLRUQCAF-UHFFFAOYSA-N
  • Monoisotopic Mass: 423.128046024
  • Average Mass: 424.339
DBSALT000543
Categories
UNIIIHP475989U
CAS number17617-23-1
WeightAverage: 387.878
Monoisotopic: 387.151368285
Chemical FormulaC21H23ClFN3O
InChI KeyInChIKey=SAADBVWGJQAEFS-UHFFFAOYSA-N
InChI
InChI=1S/C21H23ClFN3O/c1-3-25(4-2)11-12-26-19-10-9-15(22)13-17(19)21(24-14-20(26)27)16-7-5-6-8-18(16)23/h5-10,13H,3-4,11-12,14H2,1-2H3
IUPAC Name
7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-2,3-dihydro-1H-1,4-benzodiazepin-2-one
SMILES
CCN(CC)CCN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzodiazepines
Sub Class1,4-benzodiazepines
Direct Parent1,4-benzodiazepines
Alternative Parents
Substituents
  • 1,4-benzodiazepine
  • Halobenzene
  • Fluorobenzene
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl fluoride
  • Aryl chloride
  • Tertiary carboxylic acid amide
  • Tertiary aliphatic amine
  • Tertiary amine
  • Lactam
  • Ketimine
  • Carboxamide group
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organochloride
  • Organohalogen compound
  • Imine
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor short-term and intermittent use in patients with recurring insomnia and poor sleeping habits
PharmacodynamicsFlurazepam, a benzodiazepine derivative, is a hypnotic agent which does not appear to decrease dream time as measured by rapid eye movements (REM). Furthermore, it decreases sleep latency and number of awakenings for a consequent increase in total sleep time.
Mechanism of actionFlurazepam binds to an allosteric site on GABA-A receptors. Binding potentiates the action of GABA on GABA-A receptors by opening the chloride channel within the receptor, causing chloride influx and hyperpolarization.
Related Articles
AbsorptionFlurazepam hydrochloride is rapidly (30 minutes) absorbed from the gastrointestinal tract
Volume of distributionNot Available
Protein binding83%
Metabolism

Flurazepam is rapidly metabolized and is excreted primarily in the urine. Both hydroxyethyl flurazepam (the major metabolite) and N-desalkyl flurazepam are active. The N-desalkyl metabolite is slowly excreted in the urine as the conjugated form

SubstrateEnzymesProduct
Flurazepam
Not Available
Hydroxyethyl flurazepamDetails
Flurazepam
Not Available
N-desalkyl flurazepamDetails
Route of eliminationFlurazepam is rapidly metabolized and is excreted primarily in the urine. Less than 1% of the dose is excreted in the urine as N1-desalkyl-flurazepam.
Half lifeThe mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours
ClearanceNot Available
ToxicityComa, confusion, low blood pressure, sleepiness
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9898
Caco-2 permeable+0.6115
P-glycoprotein substrateSubstrate0.8553
P-glycoprotein inhibitor IInhibitor0.9455
P-glycoprotein inhibitor IIInhibitor0.6624
Renal organic cation transporterInhibitor0.6523
CYP450 2C9 substrateNon-substrate0.7716
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7794
CYP450 1A2 substrateInhibitor0.5194
CYP450 2C9 inhibitorNon-inhibitor0.7112
CYP450 2D6 inhibitorNon-inhibitor0.5469
CYP450 2C19 inhibitorInhibitor0.5082
CYP450 3A4 inhibitorInhibitor0.6347
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6231
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.7597
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5654 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9528
hERG inhibition (predictor II)Inhibitor0.7183
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Valeant pharmaceuticals international
  • Halsey drug co inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Purepac pharmaceutical co
  • Sandoz inc
  • Superpharm corp
  • Usl pharma inc
  • Warner chilcott inc
  • Warner chilcott div warner lambert co
  • Watson laboratories inc
  • West ward pharmaceutical corp
Packagers
Dosage forms
FormRouteStrength
Capsuleoral30 mg/1
Capsuleoral15 mg/1
Capsuleoral15 mg
Capsuleoral30 mg
Tablet15 mg
Tablet30 mg
Prices
Unit descriptionCostUnit
Dalmane 30 mg capsule2.01USD capsule
Dalmane 15 mg capsule1.79USD capsule
Flurazepam HCl 15 mg capsule0.43USD capsule
Flurazepam HCl 30 mg capsule0.4USD capsule
Flurazepam 30 mg capsule0.34USD capsule
Flurazepam 15 mg capsule0.28USD capsule
Apo-Flurazepam 30 mg Capsule0.1USD capsule
Apo-Flurazepam 15 mg Capsule0.08USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point190-220British Patent 1,040,548.
water solubility500 mg/mL (HCl salt)Not Available
logP3.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.01 mg/mLALOGPS
logP3.81ALOGPS
logP3.95ChemAxon
logS-4.6ALOGPS
pKa (Strongest Basic)8.71ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area35.91 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity107.54 m3·mol-1ChemAxon
Polarizability41.22 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Fryer, R. and Sternbach, L.H.; U.S. Patent 3,567,710; March 2, 1971; assigned to Hoffman-La Roche, Inc.

General References
  1. Rickels K: The clinical use of hypnotics: indications for use and the need for a variety of hypnotics. Acta Psychiatr Scand Suppl. 1986;332:132-41. [PubMed:2883820 ]
  2. Vermeeren A: Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs. 2004;18(5):297-328. [PubMed:15089115 ]
  3. Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines]. Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. [PubMed:2570451 ]
  4. Rooke KC: The use of flurazepam (dalmane) as a substitute for barbiturates and methaqualone/diphenhydramine (mandrax) in general practice. J Int Med Res. 1976;4(5):355-9. [PubMed:18375 ]
  5. Olive G, Dreux C: [Pharmacologic bases of use of benzodiazepines in pereinatal medicine]. Arch Fr Pediatr. 1977 Jan;34(1):74-89. [PubMed:851373 ]
  6. Link [Link]
External Links
ATC CodesN05CD01
AHFS Codes
  • 28:24.08
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (50.5 KB)
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Flurazepam is combined with 7-Nitroindazole.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Flurazepam.
AcepromazineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Aceprometazine.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Flurazepam.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Flurazepam.
adipiplonThe risk or severity of adverse effects can be increased when Flurazepam is combined with adipiplon.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Flurazepam.
AgomelatineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Agomelatine.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Flurazepam.
AlfaxaloneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Flurazepam is combined with Alfentanil.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Flurazepam.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Flurazepam is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Flurazepam.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Flurazepam.
AminophyllineThe therapeutic efficacy of Flurazepam can be decreased when used in combination with Aminophylline.
AmiodaroneThe metabolism of Flurazepam can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Flurazepam is combined with Amisulpride.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Flurazepam.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Flurazepam.
AmobarbitalThe risk or severity of adverse effects can be increased when Flurazepam is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Flurazepam is combined with Amperozide.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Flurazepam.
AprepitantThe serum concentration of Flurazepam can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Flurazepam is combined with Aripiprazole.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Flurazepam.
ArticaineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Asenapine.
AtazanavirThe metabolism of Flurazepam can be decreased when combined with Atazanavir.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Flurazepam.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Flurazepam.
AtomoxetineThe metabolism of Flurazepam can be decreased when combined with Atomoxetine.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Flurazepam.
AzaperoneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Azaperone.
AzelastineFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Flurazepam.
BaclofenThe risk or severity of adverse effects can be increased when Flurazepam is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Flurazepam is combined with Barbital.
BenzocaineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Benzocaine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Flurazepam is combined with Benzyl alcohol.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Flurazepam.
BexaroteneThe serum concentration of Flurazepam can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Flurazepam can be decreased when combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Flurazepam.
BortezomibThe metabolism of Flurazepam can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Flurazepam can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Flurazepam.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Flurazepam.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Flurazepam is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.
BrimonidineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Bromazepam.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Flurazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Flurazepam.
BuprenorphineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Flurazepam.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Flurazepam.
ButacaineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Flurazepam is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Flurazepam is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Flurazepam is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Flurazepam.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Flurazepam.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Flurazepam.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Flurazepam.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Flurazepam.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Flurazepam.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Flurazepam.
CarbinoxamineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Flurazepam is combined with Carfentanil.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Flurazepam.
CarisoprodolThe risk or severity of adverse effects can be increased when Flurazepam is combined with Carisoprodol.
CeritinibThe serum concentration of Flurazepam can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Flurazepam.
CetirizineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Flurazepam is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Flurazepam.
ChlormezanoneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Chloroprocaine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Chlorphenamine.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Flurazepam.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Flurazepam.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Chlorzoxazone.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Flurazepam.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Flurazepam.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Flurazepam.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Flurazepam.
CitalopramThe risk or severity of adverse effects can be increased when Flurazepam is combined with Citalopram.
ClarithromycinThe metabolism of Flurazepam can be decreased when combined with Clarithromycin.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Flurazepam.
ClemastineThe metabolism of Flurazepam can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Flurazepam is combined with Clidinium.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Flurazepam.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Flurazepam.
clomethiazoleThe risk or severity of adverse effects can be increased when Flurazepam is combined with clomethiazole.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Flurazepam.
ClomipramineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Clonazepam.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Flurazepam.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Flurazepam.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Flurazepam.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Flurazepam.
ClotrimazoleThe metabolism of Flurazepam can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Flurazepam.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Flurazepam.
CobicistatThe metabolism of Flurazepam can be decreased when combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Flurazepam.
CocaineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Flurazepam.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Flurazepam.
ConivaptanThe serum concentration of Flurazepam can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Flurazepam.
CrizotinibThe metabolism of Flurazepam can be decreased when combined with Crizotinib.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Flurazepam.
CyclizineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Cyclobenzaprine.
CyclosporineThe metabolism of Flurazepam can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Flurazepam.
CyproheptadineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Cyproheptadine.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Flurazepam.
DabrafenibThe serum concentration of Flurazepam can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Flurazepam.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Flurazepam.
DantroleneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dantrolene.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Flurazepam.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Flurazepam.
DapoxetineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dapoxetine.
DarunavirThe metabolism of Flurazepam can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Flurazepam can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Flurazepam.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Flurazepam.
DeferasiroxThe serum concentration of Flurazepam can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Flurazepam can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Flurazepam is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Detomidine.
DexamethasoneThe serum concentration of Flurazepam can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Flurazepam.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Flurazepam.
DextromoramideThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Flurazepam.
DezocineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dezocine.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Flurazepam.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Flurazepam.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Flurazepam.
DifenoxinThe risk or severity of adverse effects can be increased when Flurazepam is combined with Difenoxin.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Flurazepam.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Flurazepam.
DihydrocodeineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Flurazepam can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dihydromorphine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Flurazepam.
DiltiazemThe metabolism of Flurazepam can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Flurazepam.
DimenhydrinateThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Flurazepam is combined with Diphenoxylate.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Flurazepam.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Flurazepam.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Flurazepam.
DoramectinThe risk or severity of adverse effects can be increased when Flurazepam is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Flurazepam is combined with Doxepin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Flurazepam.
DoxycyclineThe metabolism of Flurazepam can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.
DoxylamineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Flurazepam is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.
DronedaroneThe metabolism of Flurazepam can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Flurazepam.
DrotebanolThe risk or severity of adverse effects can be increased when Flurazepam is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Flurazepam.
DyphyllineThe therapeutic efficacy of Flurazepam can be decreased when used in combination with Dyphylline.
EcgonineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Flurazepam is combined with ECGONINE METHYL ESTER.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Flurazepam.
EfavirenzThe serum concentration of Flurazepam can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Flurazepam is combined with Efavirenz.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Flurazepam.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Flurazepam.
EntacaponeThe risk or severity of adverse effects can be increased when Flurazepam is combined with Entacapone.
EnzalutamideThe serum concentration of Flurazepam can be decreased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Flurazepam.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Flurazepam.
ErythromycinThe metabolism of Flurazepam can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Flurazepam.
EscitalopramThe risk or severity of adverse effects can be increased when Flurazepam is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Flurazepam can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Estazolam.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Flurazepam.
EstriolThe serum concentration of Estriol can be increased when it is combined with Flurazepam.
EstroneThe serum concentration of Estrone can be increased when it is combined with Flurazepam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Flurazepam.
EthanolFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Flurazepam.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Flurazepam.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Flurazepam.
EthosuximideThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Flurazepam.
EtoperidoneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Etoperidone.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Flurazepam.
EtorphineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Etorphine.
EtravirineThe serum concentration of Flurazepam can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Flurazepam.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Flurazepam.
EzogabineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Flurazepam is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Flurazepam is combined with Fentanyl.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Flurazepam.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Flurazepam.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Flurazepam.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Flurazepam.
FlibanserinThe risk or severity of adverse effects can be increased when Flurazepam is combined with Flibanserin.
FluconazoleThe metabolism of Flurazepam can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flurazepam is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Fluspirilene.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Flurazepam.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Flurazepam is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Fluvoxamine.
FluvoxamineThe metabolism of Flurazepam can be decreased when combined with Fluvoxamine.
FosamprenavirThe serum concentration of Flurazepam can be increased when it is combined with Fosamprenavir.
FosaprepitantThe serum concentration of Flurazepam can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Flurazepam.
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Flurazepam.
FospropofolThe risk or severity of adverse effects can be increased when Flurazepam is combined with Fospropofol.
Fusidic AcidThe serum concentration of Flurazepam can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Flurazepam is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Flurazepam is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Flurazepam is combined with Gamma Hydroxybutyric Acid.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Flurazepam.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Flurazepam.
GlutethimideThe risk or severity of adverse effects can be increased when Flurazepam is combined with Glutethimide.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Flurazepam.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Flurazepam.
GuanfacineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Halazepam.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Flurazepam.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Flurazepam.
HalothaneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Flurazepam is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Flurazepam is combined with Hexobarbital.
HydrocodoneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Hydrocodone.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Flurazepam.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Flurazepam.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.
HydroxyzineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Hydroxyzine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Flurazepam.
IdelalisibThe serum concentration of Flurazepam can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Iloperidone.
ImatinibThe metabolism of Flurazepam can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Flurazepam.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Flurazepam.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Flurazepam.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Flurazepam.
IndalpineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Indalpine.
IndinavirThe metabolism of Flurazepam can be decreased when combined with Indinavir.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Flurazepam.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Flurazepam.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Flurazepam.
IsavuconazoniumThe metabolism of Flurazepam can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Isoflurane.
IsradipineThe metabolism of Flurazepam can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Flurazepam can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Flurazepam can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Flurazepam.
KetamineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Flurazepam.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Flurazepam.
KetobemidoneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ketobemidone.
KetoconazoleThe metabolism of Flurazepam can be decreased when combined with Ketoconazole.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Flurazepam.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Flurazepam.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Flurazepam.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Flurazepam.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Flurazepam.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Flurazepam.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Flurazepam.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Flurazepam.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Flurazepam.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Flurazepam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Flurazepam is combined with Levodopa.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Flurazepam.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Flurazepam is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Flurazepam is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Flurazepam is combined with Levorphanol.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Flurazepam.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Flurazepam.
LithiumThe risk or severity of adverse effects can be increased when Flurazepam is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Flurazepam is combined with Lofentanil.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Flurazepam.
LopinavirThe metabolism of Flurazepam can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Flurazepam.
LosartanThe serum concentration of Losartan can be increased when it is combined with Flurazepam.
LovastatinThe metabolism of Flurazepam can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Flurazepam.
Lu AA21004The risk or severity of adverse effects can be increased when Flurazepam is combined with Lu AA21004.
LuliconazoleThe serum concentration of Flurazepam can be increased when it is combined with Luliconazole.
LurasidoneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Flurazepam is combined with Magnesium Sulfate.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Flurazepam.
MaprotilineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Flurazepam is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Flurazepam.
MesoridazineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Metaxalone.
MethadoneFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Flurazepam.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Flurazepam is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Flurazepam is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Flurazepam.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Flurazepam.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Flurazepam is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Flurazepam is combined with Methylphenobarbital.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Flurazepam.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Flurazepam.
MetyrosineFlurazepam may increase the sedative activities of Metyrosine.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Flurazepam.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Flurazepam.
MifepristoneThe metabolism of Flurazepam can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Flurazepam is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Flurazepam.
MirtazapineFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Flurazepam.
MitotaneThe serum concentration of Flurazepam can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Flurazepam.
ModafinilThe serum concentration of Flurazepam can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Molindone.
MorphineThe serum concentration of Morphine can be increased when it is combined with Flurazepam.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Flurazepam.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Flurazepam.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.
NabiloneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Nabilone.
NadololThe serum concentration of Nadolol can be increased when it is combined with Flurazepam.
NafcillinThe serum concentration of Flurazepam can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Nalbuphine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Flurazepam.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Flurazepam.
NefazodoneThe metabolism of Flurazepam can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Flurazepam can be decreased when combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Flurazepam.
NetupitantThe serum concentration of Flurazepam can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Flurazepam can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Flurazepam.
NicotineThe metabolism of Flurazepam can be decreased when combined with Nicotine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Flurazepam.
NilotinibThe metabolism of Flurazepam can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Flurazepam.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Flurazepam.
NitrazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Flurazepam is combined with Nitrous oxide.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Flurazepam.
NormethadoneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Flurazepam.
OlaparibThe metabolism of Flurazepam can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Olopatadine.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Flurazepam.
OndansetronThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Flurazepam is combined with Opium.
OrphenadrineFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Flurazepam.
OsanetantThe risk or severity of adverse effects can be increased when Flurazepam is combined with Osanetant.
OsimertinibThe serum concentration of Flurazepam can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Oxazepam.
OxprenololThe risk or severity of adverse effects can be increased when Flurazepam is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Oxybuprocaine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Flurazepam.
OxymorphoneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Oxymorphone.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Flurazepam.
PalbociclibThe serum concentration of Flurazepam can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Paliperidone.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Flurazepam.
ParaldehydeFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Flurazepam.
ParoxetineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Flurazepam.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Flurazepam.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Flurazepam.
PerampanelThe risk or severity of adverse effects can be increased when Flurazepam is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Flurazepam is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Flurazepam.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Flurazepam.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Flurazepam.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Flurazepam is combined with Phenoxyethanol.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Flurazepam.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Flurazepam.
PimozideThe risk or severity of adverse effects can be increased when Flurazepam is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Pipotiazine.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Flurazepam.
PizotifenThe risk or severity of adverse effects can be increased when Flurazepam is combined with Pizotifen.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Flurazepam.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Flurazepam.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Flurazepam.
PosaconazoleThe metabolism of Flurazepam can be decreased when combined with Posaconazole.
PramipexoleFlurazepam may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Pramocaine.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Flurazepam.
PrazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Prazepam.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Flurazepam.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Flurazepam.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Flurazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Flurazepam.
PrilocaineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Prilocaine.
PrimidoneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Procaine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Flurazepam.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Flurazepam.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Flurazepam.
PromethazineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Proparacaine.
PropofolThe risk or severity of adverse effects can be increased when Flurazepam is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Propoxycaine.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Flurazepam.
ProtriptylineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Flurazepam.
PSD502The risk or severity of adverse effects can be increased when Flurazepam is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Quazepam.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Flurazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Flurazepam.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Flurazepam.
QuinineThe serum concentration of Quinine can be increased when it is combined with Flurazepam.
RamelteonThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ramelteon.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Flurazepam.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Flurazepam.
RanolazineThe metabolism of Flurazepam can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Flurazepam is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Flurazepam.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Flurazepam.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Flurazepam.
RifabutinThe metabolism of Flurazepam can be increased when combined with Rifabutin.
RifampicinThe metabolism of Flurazepam can be increased when combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Flurazepam.
RifapentineThe metabolism of Flurazepam can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Flurazepam.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Flurazepam.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Flurazepam.
RitonavirThe serum concentration of Flurazepam can be increased when it is combined with Ritonavir.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Flurazepam.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Flurazepam.
RomifidineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Romifidine.
RopiniroleFlurazepam may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Flurazepam.
RotigotineFlurazepam may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Flurazepam.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Flurazepam is combined with S-Ethylisothiourea.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Flurazepam.
SaquinavirThe serum concentration of Flurazepam can be increased when it is combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Flurazepam.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Flurazepam.
SertindoleThe risk or severity of adverse effects can be increased when Flurazepam is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Sevoflurane.
SildenafilThe metabolism of Flurazepam can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Flurazepam.
SiltuximabThe serum concentration of Flurazepam can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Flurazepam can be increased when it is combined with Simeprevir.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Flurazepam.
Sodium oxybateFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Flurazepam.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Flurazepam.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Flurazepam.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Flurazepam.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Flurazepam.
St. John's WortThe serum concentration of Flurazepam can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Flurazepam is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Flurazepam is combined with Sufentanil.
SulfisoxazoleThe metabolism of Flurazepam can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Flurazepam.
SuvorexantThe risk or severity of adverse effects can be increased when Flurazepam is combined with Suvorexant.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Flurazepam.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Flurazepam.
TapentadolThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tasimelteon.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Flurazepam.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Flurazepam.
TeduglutideThe serum concentration of Flurazepam can be increased when it is combined with Teduglutide.
TelaprevirThe metabolism of Flurazepam can be decreased when combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Flurazepam.
TelithromycinThe metabolism of Flurazepam can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Flurazepam.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Flurazepam.
TetrabenazineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tetrodotoxin.
ThalidomideFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Flurazepam.
TheophyllineThe therapeutic efficacy of Flurazepam can be decreased when used in combination with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Flurazepam is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Flurazepam.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Flurazepam.
ThiothixeneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tiagabine.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Flurazepam.
TiclopidineThe metabolism of Flurazepam can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tiletamine.
TimololThe serum concentration of Timolol can be increased when it is combined with Flurazepam.
TizanidineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tizanidine.
TocilizumabThe serum concentration of Flurazepam can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tolcapone.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Flurazepam.
TopiramateThe risk or severity of adverse effects can be increased when Flurazepam is combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Flurazepam.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Flurazepam.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Flurazepam.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tranylcypromine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Flurazepam.
TrazodoneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Triazolam.
TrifluoperazineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Flurazepam.
TrimipramineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Triprolidine.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Flurazepam.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Flurazepam.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Flurazepam.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Flurazepam.
VenlafaxineThe metabolism of Flurazepam can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Flurazepam.
VerapamilThe metabolism of Flurazepam can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Flurazepam.
VigabatrinThe risk or severity of adverse effects can be increased when Flurazepam is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Vilazodone.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Flurazepam.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Flurazepam.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Flurazepam.
VoriconazoleThe metabolism of Flurazepam can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Xylazine.
YohimbineThe therapeutic efficacy of Flurazepam can be decreased when used in combination with Yohimbine.
ZaleplonThe risk or severity of adverse effects can be increased when Flurazepam is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ziconotide.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Flurazepam.
ZimelidineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Zimelidine.
ZiprasidoneThe metabolism of Flurazepam can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Flurazepam.
ZonisamideThe risk or severity of adverse effects can be increased when Flurazepam is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Flurazepam is combined with Zuclopenthixol.
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular Weight:
51325.85 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular Weight:
55164.055 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA4
Uniprot ID:
P48169
Molecular Weight:
61622.645 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transporter activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA5
Uniprot ID:
P31644
Molecular Weight:
52145.645 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA6
Uniprot ID:
Q16445
Molecular Weight:
51023.69 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRB1
Uniprot ID:
P18505
Molecular Weight:
54234.085 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB2
Uniprot ID:
P47870
Molecular Weight:
59149.895 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-gated chloride ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB3
Uniprot ID:
P28472
Molecular Weight:
54115.04 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRG1
Uniprot ID:
Q8N1C3
Molecular Weight:
53594.49 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRG2
Uniprot ID:
P18507
Molecular Weight:
54161.78 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRG3
Uniprot ID:
Q99928
Molecular Weight:
54288.16 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRD
Uniprot ID:
O14764
Molecular Weight:
50707.835 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRE
Uniprot ID:
P78334
Molecular Weight:
57971.175 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. In the uterus, the function of the receptor appears to be related to tissue contractility. The binding of this pI subunit with other GABA(A) receptor subunits alters the sensitivity of recombinant receptors to ...
Gene Name:
GABRP
Uniprot ID:
O00591
Molecular Weight:
50639.735 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-1 GABA receptor could play a role in retinal neurotransmission.
Gene Name:
GABRR1
Uniprot ID:
P24046
Molecular Weight:
55882.91 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-2 GABA receptor could play a role in retinal neurotransmission.
Gene Name:
GABRR2
Uniprot ID:
P28476
Molecular Weight:
54150.41 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRR3
Uniprot ID:
A8MPY1
Molecular Weight:
54271.1 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transmembrane signaling receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRQ
Uniprot ID:
Q9UN88
Molecular Weight:
72020.875 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Capello S, Henderson L, DeGrazia F, Liberato D, Garland W, Town C: The effect of the cytochrome P-450 suicide inactivator, 1-aminobenzotriazole, on the in vivo metabolism and pharmacologic activity of flurazepam. Drug Metab Dispos. 1990 Mar-Apr;18(2):190-6. [PubMed:1971572 ]
  2. Linder CD, Renaud NA, Hutzler JM: Is 1-aminobenzotriazole an appropriate in vitro tool as a nonspecific cytochrome P450 inactivator? Drug Metab Dispos. 2009 Jan;37(1):10-3. doi: 10.1124/dmd.108.024075. Epub 2008 Oct 20. [PubMed:18936109 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Capello S, Henderson L, DeGrazia F, Liberato D, Garland W, Town C: The effect of the cytochrome P-450 suicide inactivator, 1-aminobenzotriazole, on the in vivo metabolism and pharmacologic activity of flurazepam. Drug Metab Dispos. 1990 Mar-Apr;18(2):190-6. [PubMed:1971572 ]
  2. Linder CD, Renaud NA, Hutzler JM: Is 1-aminobenzotriazole an appropriate in vitro tool as a nonspecific cytochrome P450 inactivator? Drug Metab Dispos. 2009 Jan;37(1):10-3. doi: 10.1124/dmd.108.024075. Epub 2008 Oct 20. [PubMed:18936109 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Quaternary ammonium group transmembrane transporter activity
Specific Function:
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridiniu...
Gene Name:
SLC22A2
Uniprot ID:
O15244
Molecular Weight:
62579.99 Da
References
  1. Zolk O, Solbach TF, Konig J, Fromm MF: Functional characterization of the human organic cation transporter 2 variant p.270Ala>Ser. Drug Metab Dispos. 2009 Jun;37(6):1312-8. doi: 10.1124/dmd.108.023762. Epub 2009 Feb 27. [PubMed:19251820 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23